2023
Clonal competition and disrupted molecular processes in chronic lymphocytic leukemia.
ZÁVACKÁ, Kristýna, Petr TAUŠ, Karol PÁL, Jakub Paweł PORC, Šárka PAVLOVÁ et. al.Basic information
Original name
Clonal competition and disrupted molecular processes in chronic lymphocytic leukemia.
Authors
ZÁVACKÁ, Kristýna (203 Czech Republic, belonging to the institution), Petr TAUŠ (203 Czech Republic, belonging to the institution), Karol PÁL (703 Slovakia, belonging to the institution), Jakub Paweł PORC (616 Poland, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Kamila STRÁNSKÁ (203 Czech Republic, belonging to the institution), Marcela ŽENATOVÁ (203 Czech Republic, belonging to the institution), Boris TICHÝ (203 Czech Republic, belonging to the institution), Nicolas BLAVET (250 France, belonging to the institution), Anna PANOVSKÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Karla PLEVOVÁ (203 Czech Republic, belonging to the institution)
Edition
XXVIIth Biochemistry congress, 2023
Other information
Language
English
Type of outcome
Conference abstract
Field of Study
30204 Oncology
Country of publisher
Slovakia
Confidentiality degree
is not subject to a state or trade secret
References:
RIV identification code
RIV/00216224:14740/23:00131784
Organization unit
Central European Institute of Technology
ISBN
978-80-8240-048-2
Keywords in English
Chronic lymphocytic leukemia; TP53 gene;
Tags
Tags
International impact, Reviewed
Changed: 24/3/2024 12:54, Mgr. Eva Dubská
Abstract
V originále
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. Due to dynamic clonal changes in a leukemic cell population over time, CLL is characterized by a highly variable clinical course. The expansion of subclones with different gene mutations, many of which are non-recurrent, makes CLL challenging to treat. We aimed to describe the clonal evolution in CLL, focusing on specific treatments and different stages of the disease. As defects in the TP53 gene are strong predictive and prognostic markers in CLL and drive chemoimmunotherapy resistance, we particularly studied factors influencing the clonal development of TP53-mutated subclones.
Links
| LX22NPO5102, research and development project |
| ||
| MUNI/A/1224/2022, interní kód MU |
| ||
| NU21-08-00237, research and development project |
|
